Latest Reimbursement News

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.

Spacetalk Ltd has secured a $428,853 R&D tax rebate from the Australian Taxation Office, reinforcing its commitment to innovation while reporting a 16% increase in Annual Recurring Revenue and significant cost reductions.

Inca Minerals has entered a binding agreement to acquire Stunalara Metals via an off-market takeover bid, aiming to expand its portfolio with high-grade gold and antimony exploration assets in North Queensland and beyond.

AustChina Holdings has entered a binding agreement to acquire Penwortham Exploration, gaining access to promising gold-antimony and base metals projects in Tasmania’s prolific mining districts. The move positions AustChina to leverage modern exploration techniques on historically rich targets.

OncoSil Medical has secured authorization for 120 German hospitals to negotiate funding for its pancreatic cancer treatment device, marking a 43% increase from last year and signaling growing acceptance in Germany’s healthcare system.

European Metals Holdings has made significant strides in developing its Cinovec Lithium Project, announcing a strategic relocation of its processing plant and ongoing enhancements to production capacity and cost efficiency. The Definitive Feasibility Study is on track for mid-2025 completion, promising a clearer outlook on the project's economic potential.

EV Resources has secured a 70% stake in the Los Lirios Antimony Mine in Mexico and reported promising geophysical survey results at its Parag Copper-Molybdenum Project in Peru, setting the stage for accelerated exploration and development.

Juno Minerals Limited reports steady progress on its Mount Mason hematite and Mount Ida lithium projects, securing government funding and revising logistics to streamline development. The company also raised $818,754 through a share placement, ending the quarter with $2.37 million in cash.

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.

Papyrus Australia Ltd reported a $284,000 net cash outflow for the December 2024 quarter, reflecting abnormal expenses but maintaining a solid funding runway through existing facilities and strategic initiatives.

Nova Eye Medical Limited is raising A$6.6 million to strengthen its financial position following resolved supply chain disruptions, while reporting strong sales growth and nearing profitability in its glaucoma division.

Nova Eye Medical reports a robust 39% increase in global sales driven by strong U.S. market demand and secures $6.6 million in fresh capital to fuel expansion and product development.